It was the objective of this study to evaluate MR-guided, percutaneous
ethanol injection of
hepatocellular carcinoma in ten patients scheduled for
liver transplantation. Using a 0.2 T open MR scanner (Magnetom Open, Siemens Medical Systems, Erlangen, Germany) and percutaneous instillation of
ethanol, 12 liver
tumors (median
tumor volume, 6.3; range, 0.6-43.2 ccm) were treated. Coagulation
necrosis, morbidity, and post-transplant histology were assessed. No major complications were observed. A mean of 16.4+/-11.4 ml
ethanol was injected for each
tumor. The median volume of the ablation
necrosis was 12.3 (range, 0.3-48.3) ccm. Three
tumors were retreated and complete radiological
necrosis before
liver transplantation was found in eight of 12
tumors (67%). One patient developed multifocal disease and was excluded from
transplantation; thus nine of ten patients underwent
liver transplantation within 3.9+/-3.1 months. In the explants, satellite nodules (n = 2), new liver
tumors (n = 2) and a complete
necrosis were found in five of 12 treated
tumors (42%). During follow-up (median 41.3; range, 0.4-86.1 months), three patients died, but no
tumor-seeding or post-
transplantation recurrence occurred. MR-guided
ethanol injection is feasible, and may delay
tumor progression. However, the local recurrence rate is high, and the spatial resolution of a low-field MR scanner limits the detection of small
tumors.